All In Biotech

Drug Trial Radar · NCT05535244

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Oct 17, 2022

Primary completion

Feb 26, 2027

Study completion Feb 26, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.

Conditions

  • Multiple Myeloma

Interventions

  • CevostamabDrug

    Cevostamab will be administered by IV infusion in 21-day cycles.

  • TocilizumabDrug

    Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) as Determined by the InvestigatorTime frame: Baseline up to approximately 2 years
  2. Percentage of Participants with Adverse EventsTime frame: Baseline up to approximately 2 years

Locations

27 sites in 8 countries. Site status is shown where the registry gives one.

  • University of Colorado

    Aurora, Colorado

  • Mayo Clinic-Jacksonville

    Jacksonville, Florida

  • University of Maryland Greenebaum Cancer Center

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • Icahn School of Medicine at Mount Sinai (ISMMS)

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Tennessee Oncology - Nashville

    Nashville, Tennessee

  • Hunstman Cancer Institute

    Salt Lake City, Utah

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • St Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • CHU NANTES - Hôtel Dieu

    Nantes, France

  • APHP - Hospital Saint Louis

    Paris, France

  • CHU de Poitiers - La Miletrie

    Poitiers, France

  • Klinik der Uni zu Köln

    Cologne, Germany

  • Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II

    Hamburg, Germany

  • Universitätsklinikum Würzburg

    Würzburg, Germany

  • Hadassah Ein Karem Hospital

    Jerusalem, Israel

  • Sheba Medical Center

    Ramat Gan, Israel

  • Sourasky Medical Centre

    Tel Aviv, Israel

  • Policlinico S.Orsola-Malpighi

    Bologna, Emilia-Romagna, Italy

  • Asst Papa Giovanni Xxiii

    Bergamo, Lombardy, Italy

  • Fond. IRCCS Istituto Nazionale Tumori

    Milan, Lombardy, Italy

  • A.O. Città della Salute e della Scienza D - Osp. S. Giov. Battista Molinette

    Turin, Piedmont, Italy

  • Hospital Clínic i Provincial

    Barcelona, Spain

  • Hospital Univ. 12 de Octubre

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.